M. Smith

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

F. Saad, T. Tammela, E. Crawford, 2022, The New England journal of medicine.

Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN

F. Saad, B. Hadaschik, F. Feng, 2021, European Urology.

Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.

S. Srinivasan, Robert J. Jones, G. Niegisch, 2022, Journal of Clinical Oncology.

Platelet Aggregation Assays Do Not Reliably Diagnose Platelet Delta Granule Storage Pool Deficiency

L. Yoxtheimer, W. Gunning, M. Smith, 2020, Journal of hematology.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

H. Scher, D. Danila, O. Ståhl, 2022, The Lancet. Oncology.

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations.

E. Small, D. Rathkopf, D. Olmos, 2022, Journal of Clinical Oncology.

CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.

N. Agarwal, T. Todenhöfer, A. Lithio, 2022, Journal of Clinical Oncology.